Pulmonary Vascular Disease
12
3
3
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
8%
1 trials in Phase 3/4
75%
3 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (12)
A Study Of Clinical Implications Of Pulmonary Vascular Disease In Valvular Heart Disease
Pulmonary Hypertension in Left Heart Disease
Contrast Echocardiography During Exercise to Assess Pulmonary Blood Volume
Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry
High Altitude (HA) Residents With Pulmonary Vascular Diseseases (PVD), Pulmonary Artery Pressure (PAP) Assessed at HA (2840m) vs Sea Level (LA)
Assessing Response to Inhaled Prostacyclin With Hyperpolarized Xe MRI
HA Residents With PVD, SDB Assessed at HA (2840m) vs LA (Sea Level)
High Altitude (HA) Residents With Pulmonary Vascular Diseases (PVD), 6 Minute Walk Distance (6MWD) Assessed at 2840m (HA) With and Without Supplemental Oxygen Therapy (SOT)
HA Residents With PVD, 6MWD Assessed at HA (2840m) vs LA (Sea Level)
Non-Invasive Diagnosis of Pulmonary Vascular Disease Using Inhaled 129Xe Magnetic Resonance Imaging
Evaluation of Dynamic Pulmonary Vascular Resistance in Patients With Closed Ventricular Septal Defect
EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection